Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Brimonidine as a possible treatment for myopia

Fig. 2

Change in AL over the course of 3 weeks. B: Monocular FD, no drug; D4, and E1,2: FD + brimonidine at stated concentration, by different delivery routes. D4: FD + 40µg/µL subconjunctival; E1,2: FD + 2.0µg/µL, 4.0µg/µL intravitreal. *P < 0.05 B compared to values for all other groups. #P < 0.05 B compared to values of the other groups, excluding D4

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us